Drug Profile
Mibavademab - Regeneron Pharmaceuticals
Alternative Names: REGN-4461Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antibodies; Obesity therapies
- Mechanism of Action Leptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lipodystrophy
- No development reported Obesity
Most Recent Events
- 18 Apr 2024 Eli Lilly and Company plans a phase II trial for Obesity (Combination therapy) in the US and Mexico in May 2024 (SC) (NCT06373146)
- 02 Feb 2024 Mibavademab - Regeneron Pharmaceuticals receives Breakthrough Therapy status for Lipodystrophy in USA
- 15 Jun 2023 Efficacy and adverse event data from a phase II trial in Lipodystrophy presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)